AllerGen successfully completes mid-term review

AllerGen, the Allergy, Genes and Environment Network, has successfully passed its second mid-term review and will receive funding until 2019. Launched in 2005, the classic Network of Centres of Excellence (NCE) will receive the maximum funding allowable under (now modified) NCE rules. In 2012, it was awarded $36.6 million ($5.2 million annually) for its second seven-year tranche, which will take the McMaster Univ-based organization to FY18-19 (R$, March 29/12). Its last four years will see AllerGen scientists complete their research and focus on translating and commercializing key findings. Among its achievements to date are the Canadian Healthy Infant Longitudinal Development Study examining the early-life origins of allergies and asthma, and the Clinical Investigator Collaborative for Phase II trials of new drugs to better manage asthma and allergies....